Sunday, December 1 | 9:30 a.m.-9:40 a.m. | S1-SSNMMI01-4 | Room S405
Ga-68 FAPI-PET/CT significantly enhances the detection rate and staging of primary and metastatic breast cancer, demonstrating superior sensitivity and specificity compared with F-18 FDG-PET/CT, according to this study. Crucially, it also resulted in upstaging in 23.7% of cases, the group noted.
Madina Gabdullina, PhD, of Asfendiyarov Kazakh National Medical University in Almaty, Kazakhstan, will present an assessment of Ga-68 FAPI-PET/CT versus F-18 FDG-PET/CT in identifying primary breast cancer lesions, lymph node metastases, and distant metastases. The researchers prospectively enrolled 17 women diagnosed with breast cancer from January 2024 to April 2024. The mean age of participants was 52.5 years. Each participant underwent both scans.
The group identified 20 primary lesions and 43 metastatic lymph nodes in the patients, as well as 10 bone metastases and six liver metastases. Ga-68 FAPI-PET/CT showed a sensitivity of 100% and a specificity of 86% for primary lesions. Comparatively, F-18 FDG-PET/CT demonstrated a sensitivity of 83% and specificity of 71%. Notably, Ga-68 FAPI-PET/CT identified three primary lesions smaller than 7 mm in size, as well as outperformed F-18 FDG-PET diagnosing lymph node metastases and distant metastases.
“This superior diagnostic capability facilitates more precise treatment decisions, potentially reducing unnecessary interventions and aligning with personalized cancer care,” the researchers noted.
